Epigenomics Financials
| EPGNF Stock | USD 0.79 0.00 0.00% |
Epigenomics |
Understanding current and past Epigenomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Epigenomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Epigenomics' assets may result in an increase in income on the income statement.
Epigenomics Stock Summary
Epigenomics competes with Sotera Health, Neogen, Qiagen NV, Burning Rock, and Guardant Health. Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Geneststrasse 5, Berlin, |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Benchmark | Dow Jones Industrial |
| Website | www.epigenomics.com |
| Phone | 49 30 243 450 |
| Currency | USD - US Dollar |
Epigenomics Key Financial Ratios
There are many critical financial ratios that Epigenomics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Epigenomics AG reports annually and quarterly.Epigenomics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Epigenomics's current stock value. Our valuation model uses many indicators to compare Epigenomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Epigenomics competition to find correlations between indicators driving Epigenomics's intrinsic value. More Info.Epigenomics AG is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Epigenomics' earnings, one of the primary drivers of an investment's value.Epigenomics AG Systematic Risk
Epigenomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Epigenomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was fourty with a total number of output elements of twenty-one. The Beta measures systematic risk based on how returns on Epigenomics AG correlated with the market. If Beta is less than 0 Epigenomics generally moves in the opposite direction as compared to the market. If Epigenomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Epigenomics AG is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Epigenomics is generally in the same direction as the market. If Beta > 1 Epigenomics moves generally in the same direction as, but more than the movement of the benchmark.
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |